GHRP-2
Research chemical · Grade C
Goals
muscle, sleep
Evidence
—
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
Plasma half-life: approximately 15-30 minutes following subcutaneous injection
Primary mechanism
GHS-R1a agonism on pituitary somatotrophs → Gq/11 → PLC → IP3 + DAG → intracellular calcium release → PKC activation → GH vesicle exocytosis.